Cargando…
Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia
We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B and 14) between 1984 and 1999. The event-free survival improved significantly (p=0.003) from the first two trials conducted in the 1980s to the three more recent tria...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820159/ https://www.ncbi.nlm.nih.gov/pubmed/20010620 http://dx.doi.org/10.1038/leu.2009.252 |
_version_ | 1782177349819695104 |
---|---|
author | Pui, C-H Pei, D Sandlund, JT Ribeiro, RC Rubnitz, JE Raimondi, SC Onciu, M Campana, D Kun, LE Jeha, S Cheng, C Howard, SC Metzger, ML Bhojwani, D Downing, JR Evans, WE Relling, MV |
author_facet | Pui, C-H Pei, D Sandlund, JT Ribeiro, RC Rubnitz, JE Raimondi, SC Onciu, M Campana, D Kun, LE Jeha, S Cheng, C Howard, SC Metzger, ML Bhojwani, D Downing, JR Evans, WE Relling, MV |
author_sort | Pui, C-H |
collection | PubMed |
description | We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B and 14) between 1984 and 1999. The event-free survival improved significantly (p=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in the 1990s. Approximately 75% of patients treated in the 1980s and 80% in the 1990s were cured. Early intensive triple intrathecal therapy, together with more effective systemic therapy, including consolidation and reinduction treatment (Studies 13A and 13B) as well as dexamethasone (Study 13A), resulted in a very low rate of isolated central-nervous-system relapse rate (<2%), despite the reduced use of cranial irradiation. Factors consistently associated with treatment outcome were age, leukocyte count, immunophenotype, DNA index, and minimal residual disease level after remission induction treatment. Because of concerns about therapy-related secondary myeloid leukemia and brain tumors, in our current trials we reserve the use of etoposide for patients with refractory or relapsed leukemia undergoing hematopoietic stem cell transplantation, and cranial irradiation for those with CNS relapse. The next main challenge is to further increase cure rates while improving quality of life for all patients. |
format | Text |
id | pubmed-2820159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
record_format | MEDLINE/PubMed |
spelling | pubmed-28201592010-08-01 Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia Pui, C-H Pei, D Sandlund, JT Ribeiro, RC Rubnitz, JE Raimondi, SC Onciu, M Campana, D Kun, LE Jeha, S Cheng, C Howard, SC Metzger, ML Bhojwani, D Downing, JR Evans, WE Relling, MV Leukemia Article We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B and 14) between 1984 and 1999. The event-free survival improved significantly (p=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in the 1990s. Approximately 75% of patients treated in the 1980s and 80% in the 1990s were cured. Early intensive triple intrathecal therapy, together with more effective systemic therapy, including consolidation and reinduction treatment (Studies 13A and 13B) as well as dexamethasone (Study 13A), resulted in a very low rate of isolated central-nervous-system relapse rate (<2%), despite the reduced use of cranial irradiation. Factors consistently associated with treatment outcome were age, leukocyte count, immunophenotype, DNA index, and minimal residual disease level after remission induction treatment. Because of concerns about therapy-related secondary myeloid leukemia and brain tumors, in our current trials we reserve the use of etoposide for patients with refractory or relapsed leukemia undergoing hematopoietic stem cell transplantation, and cranial irradiation for those with CNS relapse. The next main challenge is to further increase cure rates while improving quality of life for all patients. 2009-12-10 2010-02 /pmc/articles/PMC2820159/ /pubmed/20010620 http://dx.doi.org/10.1038/leu.2009.252 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Pui, C-H Pei, D Sandlund, JT Ribeiro, RC Rubnitz, JE Raimondi, SC Onciu, M Campana, D Kun, LE Jeha, S Cheng, C Howard, SC Metzger, ML Bhojwani, D Downing, JR Evans, WE Relling, MV Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title | Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title_full | Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title_fullStr | Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title_full_unstemmed | Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title_short | Long-term results of St. Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia |
title_sort | long-term results of st. jude total therapy studies 11, 12, 13a, 13b and 14 for childhood acute lymphoblastic leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820159/ https://www.ncbi.nlm.nih.gov/pubmed/20010620 http://dx.doi.org/10.1038/leu.2009.252 |
work_keys_str_mv | AT puich longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT peid longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT sandlundjt longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT ribeirorc longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT rubnitzje longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT raimondisc longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT oncium longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT campanad longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT kunle longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT jehas longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT chengc longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT howardsc longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT metzgerml longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT bhojwanid longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT downingjr longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT evanswe longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia AT rellingmv longtermresultsofstjudetotaltherapystudies111213a13band14forchildhoodacutelymphoblasticleukemia |